Navigation Links
DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
Date:6/29/2009

ortal circulation and the superior vena cava."

Dr. Chien added, "This finding has important implications for an alternative method for treatment of pulmonary inflammatory disease, that is, the delivery of a potent glucocorticoid to the pulmonary circulation after ingestion of an oral pro-drug (BDP). Clinical trials examining this novel pulmonary delivery system in patients with inflammatory lung diseases will be of interest."

"The positive pulmonary effects that were observed were clearly of benefit to the GVHD patients," said Brian L. Hamilton, MD, PhD, Chief Medical Officer of DOR. "The publication of these pulmonary results is exciting as they lead the way to the potential development of new applications of oral BDP in a number of pulmonary inflammatory disorders, such as asthma or interstitial lung diseases, having significant market opportunity beyond the GI area."

About orBec(R)

orBec(R) represents a first-of-its-kind oral, locally acting therapy tailored to treat the gastrointestinal manifestation of GVHD, the organ system where GVHD is most frequently encountered and highly problematic. orBec(R) is intended to reduce the need for systemic immunosuppressive drugs to treat GI GVHD. Beclomethasone dipropionate (BDP) is a highly potent, topically active corticosteroid that has a local effect on inflamed tissue. BDP has been marketed in the US and worldwide since the early 1970s as the active pharmaceutical ingredient in a nasal spray and in a metered-dose inhaler for the treatment of patients with allergic rhinitis and asthma. orBec(R) is formulated for oral administration in GI GVHD patients as a single product consisting of two tablets; one tablet is intended to release BDP in the proximal portions of the GI tract, and the other tablet is intended to release BDP in the distal portions of the GI tract.

In addition to issued patents and pending worl
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
4. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
5. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
6. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
7. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
8. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
9. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
10. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 People with a ... aids achieved significant and sometimes profound improvements in their ... devices, according to a new multicenter study led by ... the study, described online ahead of print in the journal ... and private clinics in the United States ...
(Date:7/28/2015)... Research and Markets ... the "Analysis of the Global Flow Cytometry ... Globally, flow cytometry remains a popular tool ... and stem cells. But the market is witnessing ... demand from underdeveloped nations to quantitate CD4 cell ...
(Date:7/28/2015)... July 28, 2015 Deerfield Management Company, L.P. ... Fund, L.P., which will invest in groundbreaking advancements in ... diseases, cancer, and orphan diseases. The venture capital fund ... therapeutics are developed and improve the way healthcare is ... the largest healthcare-focused venture funds in the sector, will ...
(Date:7/28/2015)... MORRISTOWN, N.J. , July 28, 2015 /PRNewswire/ ... its second Phase 1 clinical trial with MMI-0100, ... that is being developed for pulmonary disorders characterized ... the United Kingdom , is ... study further evaluating the safety and tolerability of ...
Breaking Biology Technology:Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 3Analysis of the Global Flow Cytometry Market 2012-2018 with a 2014 Base Year and a 2015-2018 Forecast Period 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2
... EXEL ) announced today that that it will hold its,Third ... ET /,7:00 a.m. PT to 2:00 p.m. ET / 11:00 a.m. ... may be accessed in the Event Calendar,page under Investors at ... until 9:00 p.m. PT / 12:00,a.m. ET on January 4, 2008. ...
... MannKind,Corporation (Nasdaq: MNKD ), focused on discovering, ... that it,will present at the Piper Jaffray Healthcare Conference ... Pierre Hotel in New York, NY. Interested parties ... of the,presentation in the Investor Relations section of the ...
... LAKE, N.J., Nov. 20 Barr,Pharmaceuticals, Inc. (NYSE: ... Barr,Laboratories, Inc., has initiated a challenge of the ... 10mg, 15mg & 20mg. Focalin XR is manufactured ... Holdings Inc. Barr filed its Abbreviated New ...
Cached Biology Technology:Barr Confirms Patent Challenge of Focalin(R) XR 2Barr Confirms Patent Challenge of Focalin(R) XR 3
(Date:7/8/2015)... , July 8, 2015 Summary Pancreatic ... the fourth most fatal, with a mortality rate of ... prognosis of pancreatic cancer patients has highlighted a significant ... is not being met by the current market. ... of products with varying molecule types and mechanisms of ...
(Date:7/7/2015)... , June 30, 2015 ... has announced the addition of the "Capacitive ... offering. To this date, fingerprint sensing ... technology and fingerprint sensors are well developed. This ... sensing technology. The domain of capacitive ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) has ... Market by Application, Technology, Function & Geography - Global ... The next generation biometrics market is expected to ... 17.9% between 2015 and 2020 Travel & ... Safran SA ( France ), NEC ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... German . Infectious proteins known as prions ... disease (BSE). The culprits are "incorrectly folded" proteins that ... prion diseases are not yet fully understood. Why are ... headed by Beat Meier (ETH Zurich, Switzerland) and Raimon ...
... This release is available in French . ... the McGill University Health Centre (MUHC), McGill University and ... use of cannabinoids do not cause an increase in ... in some non-serious adverse events. Several drugs ...
... The Stowers Institute,s Rong Li Lab has discovered that a ... also have a role in the formation of cysts in ... most common life-threatening genetic diseases and has shown that ... mice. The discovery was published in the ...
Cached Biology News:Tracking prions 2Medicines derived from cannabis: a review of adverse events 2Rong Li Lab identifies new role of inflammatory protein in PKD and a possible treatment 2
Artisan™ Wash Solution (x 50) Additional Information: EU regulatory status: CE US regulatory status: IVD ...
... The Gene Cycler unit is an inexpensive personal ... for the PCR process. Lightweight, with a small ... almost anywhere, including the researcher's desk. , The ... researchers who do not have access to a ...
... Secondary Detection System is intended for use ... Antibody reagents, which contain rat and goat ... by light microscopy in paraffin-embedded tissues. The ... also be used with other rat or ...
... stain is used to stain and visualize ... gels and does not interfere with northern ... transilluminator, the stain emits a red-orange signal ... or with a CCD camera-based gel documentation ...
Biology Products: